



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

Date: 13th August, 2026

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Newspaper Publication of Financial Results for the Quarter ended 30th June, 2026.

Dear Sir/ Madam,

Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed a copy of newspaper publication in the following newspapers dated 13th August, 2026 with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the Quarter ended 30th June, 2026 approved at the meeting of Board of Directors held on Wednesday, 12th August, 2026.

1. Financial Express (English)
2. Mumbai Lakshadeep (Marathi)

Copy of the results are also uploaded on the website of our Company - www.eikolifesciences.com

Kindly take the same on your records.

Thanking you,
Yours sincerely.

For Eiko Lifesciences Limited

Chintan Doshi
Compliance officer & Company Secretary
Membership No: A36190

Encl.: Same as above



EIKO LIFESCIENCES
FEEL THE CHEMISTRY

EIKO LIFESCIENCES LIMITED

(CIN: L65993MH1977PLC258134)

Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604.

E-mail: investor.relations@eikolifesciences.com **Tel. No.:** +919082668855 **Website:** www.eikolifesciences.com

EXTRACT OF UN-AUDITED STADNALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30-06-2026

(₹ in Lakhs except EPS)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended			Year Ended	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	1,486.51	1635.79	800.60	4425.61	1,715.96	1,846.93	1,097.66	5,367.94
2	Net profit/ (Loss) for the period (before tax, before Exceptional items and before share of profit of Associates)	140.45	149.33	90.77	471.30	196.44	204.76	147.44	706.47
3	Net profit/ (Loss) before tax (after Exceptional items and after share of profit of associates)	140.45	149.33	90.77	471.30	199.93	201.87	148.50	711.77
4	Net profit/ (Loss) after tax (after Exceptional items and after share of profit of associates)	106.44	112.39	69.22	358.11	150.83	149.72	111.74	532.47
5	Total comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax), share of profit of Associates and Other Comprehensive Income (after tax)	106.44	112.39	69.22	358.11	150.83	149.72	111.74	532.47
6	Paid up equity share Capital	1,434.59	1,434.59	1,376.27	1434.59	1,434.59	1,434.59	1,376.27	1,434.59
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year.	-	-	-	4909.65	-	-	-	5,037.66
8	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.74	0.80	0.50	2.60	0.91	0.93	0.66	3.26
9	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.62	0.74	0.50	2.54	0.76	0.86	0.66	3.19

Notes:

- The above Unaudited Standalone and Consolidated Financial results for the quarter ended 30th June, 2026 were reviewed by the Audit Committee and recommended to the Board on 12th August, 2026 and thereafter approved by the Board of Directors of the Company at their meeting held on 12th August, 2026 . The Limited Audit Review Report issued by Statutory Auditor has no qualification / modification.
- These Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended)
- The above is an extract of the details format of Quarter Ended Results filed with the stock exchange under Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Financial Results for the Quarter ended 30th June, 2026 are available on stock exchange website at www.bseindia.com and also on the company's website i.e., www.eikolifesciences.com
- The Company's Consolidated Financial Results include financial results of:
 - Eiko Scientific Solutions LLP - Wholly Owned Subsidiary
 - Eikovivity Logistics Private Limited - Subsidiary
 - Reflux Pharmaceuticals Private Limited - Associate Company
 - SSM Formulations Private Limited - Associate Company

For, EIKO LIFESCIENCES LIMITED
Sd/-
Chintan Doshi
Company Secretary & Compliance Officer
A36190

Date: 12-08-2026
Place: Thane

